Jonathan T Seal

Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.

David M. Wilson, P. Bamborough, C. Chung, 2012, Journal of medicinal chemistry.

Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).

David M. Wilson, P. Bamborough, R. Prinjha, 2012, Bioorganic & medicinal chemistry letters.

Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

P. Grandi, A. Michon, I. Wall, 2021, Journal of medicinal chemistry.

Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.

A. Muir, G. Sanger, Christopher N. Johnson, 2009, Journal of medicinal chemistry.

Identification of a Novel Series of BET Family Bromodomain Inhibitors: Binding Mode and Profile of I‐BET151 (GSK1210151A).

Jonathan T Seal, Jonathan T. Seal, 2012 .

Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

P. Grandi, I. Wall, James M. Woolven, 2021, Journal of medicinal chemistry.

The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.

Michael A. Briggs, G. Macdonald, G. Sanger, 2008, Bioorganic & medicinal chemistry letters.

From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.

E. Nicodème, J. Kirilovsky, L. Trottet, 2012, Bioorganic & medicinal chemistry letters.